Response to Lenvatinib Is Associated with Optimal RelativeDose Intensity in Hepatocellular Carcinoma: Experience in Clinical Settings.
Ryu SasakiMasanori FukushimaMasafumi HaraguchiSatoshi MiumaHisamitsu MiyaakiMasaaki HidakaSusumu EguchiSatoshi MatsuoKazuaki TajimaToshihisa MatsuzakiSatsuki HashimotoKazuo OobaYuki KugiyamaHiroshi YatsuhashiYasuhide MotoyoshiMasaya ShigenoNoboru KinoshitaKazuhiko NakaoPublished in: Cancers (2019)
Because a sufficient RDI is required to achieve an OR, it is strongly recommended that lenvatinib should be administered to patients with good hepatic function and status.
Keyphrases